BIORESTORATIVE THERAPIES, INC. (BRTX) Spending and interest coverage
- R&D / revenue · 12 months: Value 2619.41%; Formula and calculation Research and development expense / revenue. Period ending 2026-03-31..
- Stock-based compensation / revenue · 12 months: Value 448.97%; Formula and calculation Share-based compensation / revenue. Period ending 2026-03-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2619.41% | Research and development expense / revenue. Period ending 2026-03-31. $9.37M ÷ $357.87K × 100 ≈ 2619.41% |
| Stock-based compensation / revenue · 12 months | 448.97% | Share-based compensation / revenue. Period ending 2026-03-31. $1.61M ÷ $357.87K × 100 ≈ 448.97% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 9.37M USD | Research and Development Expense |
| Revenue | 357.87K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 1.61M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -14.23M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $9.37M | $357.87K | $1.61M | $-14.23M | (m) | 2619.41% | 448.97% | (m) | (m) |
| 2025-12-31 | $10.09M | $359.70K | $3.33M | $-15.65M | (m) | 2806.41% | 924.56% | (m) | (m) |
| 2025-09-30 | $7.81M | $383.40K | $3.05M | $-14.51M | (m) | 2037.41% | 796.40% | (m) | (m) |
| 2025-06-30 | $6.69M | $605.20K | $2.94M | $-13.09M | (m) | 1105.45% | 485.41% | (m) | (m) |
| 2025-03-31 | $6.00M | $391.00K | $2.79M | $-12.25M | (m) | 1535.78% | 714.40% | (m) | (m) |
| 2024-12-31 | $5.35M | $401.00K | $2.81M | $-11.56M | (m) | 1333.84% | 701.39% | (m) | (m) |
| 2024-09-30 | $4.78M | $377.00K | $4.10M | $-12.09M | (m) | 1268.07% | 1087.89% | (m) | (m) |
| 2024-06-30 | $4.25M | $174.10K | $5.27M | $-12.90M | (m) | 2441.28% | 3027.86% | (m) | (m) |
| 2024-03-31 | $3.86M | $149.50K | $6.43M | $-13.55M | (m) | 2582.59% | 4302.91% | (m) | (m) |
| 2023-12-31 | $4.03M | $145.80K | $7.78M | $-15.22M | (m) | 2767.21% | 5338.11% | (m) | (m) |
| 2023-09-30 | $4.03M | $130.20K | $9.38M | $-16.68M | (m) | 3093.38% | 7201.88% | (m) | (m) |
| 2023-06-30 | $4.14M | $128.50K | $10.96M | $-18.19M | (m) | 3223.29% | 8527.37% | (m) | (m) |
| 2023-03-31 | $4.25M | $135.10K | $12.58M | $-19.70M | (m) | 3145.27% | 9308.77% | (m) | (m) |
| 2022-12-31 | $3.51M | $119.80K | $12.61M | $-18.97M | (m) | 2932.68% | 10528.27% | (m) | (m) |
| 2022-09-30 | $3.01M | $121.10K | $3.30M | $-18.30M | (m) | 2481.61% | 2725.50% | (m) | (m) |
| 2022-06-30 | $2.25M | $100.10K | $6.23M | $-17.38M | (m) | 2251.22% | 6220.83% | (m) | (m) |
| 2022-03-31 | $1.34M | $44.00K | $9.11M | $-16.31M | (m) | 3043.50% | 20693.20% | (m) | (m) |
| 2021-12-31 | $729.06K | $46.00K | $23.11M | $-26.31M | (m) | 1584.91% | 50236.86% | (m) | (m) |
| 2021-09-30 | $741.47K | $58.00K | $20.00M | $-23.15M | (m) | 1278.40% | 34474.98% | (m) | (m) |
| 2021-06-30 | $755.10K | $65.00K | $17.25M | $-20.08M | (m) | 1161.69% | 26544.29% | (m) | (m) |
| 2021-03-31 | $855.75K | $69.00K | $14.55M | $-16.99M | (m) | 1240.22% | 21082.01% | (m) | (m) |
| 2020-12-31 | $876.83K | $77.00K | $691.70K | $-2.75M | (m) | 1138.74% | 898.31% | (m) | (m) |
| 2020-09-30 | $1.11M | $92.00K | $791.91K | $-4.05M | (m) | 1211.64% | 860.77% | (m) | (m) |
| 2020-06-30 | $1.27M | $115.00K | $841.19K | $-5.26M | (m) | 1107.38% | 731.47% | (m) | (m) |
| 2020-03-31 | $1.45M | $127.00K | $1.09M | $-6.92M | (m) | 1144.61% | 861.99% | (m) | (m) |
| 2019-12-31 | $1.72M | $130.00K | $1.66M | $-8.43M | (m) | 1324.88% | 1275.79% | (m) | (m) |
| 2019-09-30 | $1.68M | $127.00K | $2.31M | $-8.45M | (m) | 1324.66% | 1821.15% | (m) | (m) |
| 2019-06-30 | $1.63M | $115.00K | $1.95M | $-7.82M | (m) | 1417.33% | 1693.80% | (m) | (m) |
| 2019-03-31 | $1.56M | $121.00K | $2.30M | $-7.75M | (m) | 1290.10% | 1902.69% | (m) | (m) |
| 2018-12-31 | $1.51M | $111.00K | $2.40M | $-7.65M | (m) | 1363.20% | 2161.61% | (m) | (m) |
| 2018-09-30 | $1.38M | $120.00K | $2.10M | $-7.04M | (m) | 1152.15% | 1745.91% | (m) | (m) |
| 2018-06-30 | $1.52M | $110.00K | $3.03M | $-7.60M | (m) | 1378.00% | 2752.45% | (m) | (m) |
| 2018-03-31 | $1.75M | $93.00K | $3.53M | $-8.12M | (m) | 1885.71% | 3793.79% | (m) | (m) |
| 2017-12-31 | $2.15M | $81.00K | $3.60M | $-8.37M | (m) | 2657.32% | 4445.44% | (m) | (m) |
| 2017-09-30 | $2.66M | $49.08K | $3.76M | $-8.67M | (m) | 5420.06% | 7652.16% | (m) | (m) |
| 2017-06-30 | $2.83M | $38.08K | $3.46M | $-8.65M | (m) | 7420.64% | 9099.33% | (m) | (m) |
| 2017-03-31 | $2.82M | $34.23K | $3.08M | $-8.22M | (m) | 8248.24% | 8999.59% | (m) | (m) |
| 2016-12-31 | $2.88M | $36.35K | $2.54M | $-7.80M | (m) | 7931.68% | 6977.82% | (m) | (m) |
| 2016-09-30 | $2.76M | $229.41K | $2.88M | $-8.72M | (m) | 1203.52% | 1257.45% | (m) | (m) |
| 2016-06-30 | $2.72M | $320.53K | $2.73M | $-8.49M | (m) | 848.74% | 850.59% | (m) | (m) |
| 2016-03-31 | $2.56M | $453.14K | $2.00M | $-7.61M | $241.78K | 565.89% | 440.30% | -31.48× | Reported |
| 2015-12-31 | $2.11M | $628.91K | $1.95M | $-7.17M | $263.58K | 334.71% | 310.81% | -27.20× | Reported |
| 2015-09-30 | $1.83M | $509.54K | $1.22M | $-5.70M | $270.36K | 358.72% | 239.65% | -21.07× | Reported |
| 2015-06-30 | $1.50M | $573.35K | $1.03M | $-5.10M | $264.49K | 262.13% | 178.98% | -19.29× | Reported |
| 2015-03-31 | $1.34M | $600.52K | $1.36M | $-5.12M | $276.78K | 223.76% | 226.13% | -18.50× | Reported |
| 2014-12-31 | $1.43M | $416.00K | $1.36M | $-4.92M | $285.27K | 343.90% | 327.00% | -17.26× | Reported |
| 2014-09-30 | $1.48M | $336.25K | $1.31M | $-4.82M | $305.64K | 441.21% | 388.43% | -15.76× | Reported |
| 2014-07-15 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $1.61M | $176.44K | $1.36M | $-5.05M | $286.90K | 911.22% | 771.12% | -17.60× | Reported |
| 2014-03-31 | $1.69M | $925.00 | $930.62K | $-4.88M | $246.54K | 182416.54% | 100607.14% | -19.80× | Reported |
| 2013-12-31 | $1.59M | $1.68K | $812.65K | $-4.75M | $371.28K | 94884.17% | 48371.85% | -12.80× | Reported |
| 2013-09-30 | $1.16M | $2.04K | $1.25M | $-5.25M | $414.18K | 56560.27% | 61342.32% | -12.67× | Reported |
| 2013-06-30 | $1.02M | $7.14K | $1.40M | $-5.32M | $530.56K | 14228.57% | 19570.35% | -10.03× | Reported |
| 2013-03-31 | $762.92K | $16.72K | $1.62M | $-5.55M | $662.58K | 4563.20% | 9701.75% | -8.37× | Reported |
| 2012-12-31 | $416.18K | $15.59K | $1.85M | $-5.57M | $591.81K | 2669.70% | 11856.09% | -9.42× | Reported |
| 2012-09-30 | $258.38K | (m) | $1.22M | $-4.57M | $565.37K | (m) | (m) | -8.08× | Reported |
| 2012-06-30 | (m) | (m) | $932.67K | $-4.21M | $467.92K | (m) | (m) | -9.00× | Reported |
| 2012-03-31 | (m) | (m) | $729.01K | $-3.86M | $362.70K | (m) | (m) | -10.64× | Reported |
| 2011-12-31 | $12.00K | (m) | $456.83K | $-3.55M | $260.01K | (m) | (m) | -13.66× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $11.62K | (m) | $895.61K | $-2.07M | $24.16K | (m) | (m) | -85.67× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |